Public Health Impact of Efluelda, a High-Dose Trivalent Influenza Vaccine (TIV-HD) Compared to Standard-Dose Trivalent Inactivated Vaccines (TIV-SD)
Author(s)
Lea Antoniali, PharmD1, Anne-Lise VATAIRE, PhD1, Laurence Allard, PharmD2, Helene Bricout, PharmD2, Fabian P. Alvarez, PhD2, Olivia Carnapete, Ms1.
1Sanofi, Gentilly, France, 2Sanofi, Lyon, France.
1Sanofi, Gentilly, France, 2Sanofi, Lyon, France.
OBJECTIVES: The objective was to estimate health outcomes (influenza cases, hospitalizations, deaths) and the cost-effectiveness of replacing the standard-dose (SD) by high-dose (HD) trivalent vaccine in adults aged 65-years and older.
METHODS: A model, validated by French HTA in April 2025, is a static-decision tree model that accounts for all relevant clinical paths during an influenza season, including: influenza cases, medical consultations, hospitalizations, mortality directly and non-directly attributable to influenza. to the model assess outcomes over a 6-month influenza season and lifetime horizon for averted deaths. The study population included 14.7 million adults aged 65years and older in France. Vaccine efficacies were derived from efficacy RCT and systematic literature reviews; vaccine coverage was based on the one from 2023_2024 season.
RESULTS: In addition to SD prevented events, HD was estimated to prevent 71,713 influenza cases; 17,033 medical consultations; 2,257 hospitalizations; 950 deaths. These prevented events were significant, considering the substantial strain on hospital capacity and resources during the influenza season. The use of HD resulted in savings of €605,509 in medical consultation and €14,229,578 in hospitalization costs. Limiting the analysis to influenza-related hospitalizations was conservative and likely underestimated the burden of the disease, as mentioned in the preferential recommendation issued by French NITAG in April 2025. When considering cardiorespiratory hospitalizations in sensitivity analysis, HD prevented 18 328 hospitalizations resulting a saving cost of €121,968,037. Considering the base-case analysis HD is cost-effective compared to TIV-SD, with an ICER of €17,533/QALY.
CONCLUSIONS: HD offers significant public health benefits over SD vaccines in adults aged 65-years and older. As hospitalizations mostly occur during the winter epidemic peak (8-10 weeks), HD may help ease seasonal hospital overcrowding and preserve healthcare capacity.
METHODS: A model, validated by French HTA in April 2025, is a static-decision tree model that accounts for all relevant clinical paths during an influenza season, including: influenza cases, medical consultations, hospitalizations, mortality directly and non-directly attributable to influenza. to the model assess outcomes over a 6-month influenza season and lifetime horizon for averted deaths. The study population included 14.7 million adults aged 65years and older in France. Vaccine efficacies were derived from efficacy RCT and systematic literature reviews; vaccine coverage was based on the one from 2023_2024 season.
RESULTS: In addition to SD prevented events, HD was estimated to prevent 71,713 influenza cases; 17,033 medical consultations; 2,257 hospitalizations; 950 deaths. These prevented events were significant, considering the substantial strain on hospital capacity and resources during the influenza season. The use of HD resulted in savings of €605,509 in medical consultation and €14,229,578 in hospitalization costs. Limiting the analysis to influenza-related hospitalizations was conservative and likely underestimated the burden of the disease, as mentioned in the preferential recommendation issued by French NITAG in April 2025. When considering cardiorespiratory hospitalizations in sensitivity analysis, HD prevented 18 328 hospitalizations resulting a saving cost of €121,968,037. Considering the base-case analysis HD is cost-effective compared to TIV-SD, with an ICER of €17,533/QALY.
CONCLUSIONS: HD offers significant public health benefits over SD vaccines in adults aged 65-years and older. As hospitalizations mostly occur during the winter epidemic peak (8-10 weeks), HD may help ease seasonal hospital overcrowding and preserve healthcare capacity.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE623
Topic
Economic Evaluation, Epidemiology & Public Health
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Vaccines